Celltrion, Inc.

Celltrion, Inc.

068270.KS - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$48.81T
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Celltrion, Inc.Celltrion, Inc.37.30.33%7%9.60.2
$191768.64

Current Fair Value

10.4% downside

Overvalued by 10.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$48.81 Trillion
Enterprise Value$51.60 Trillion
Annual dividend$714.29
Dividend yield0.33%
Earnings per Share$4466.05
Beta0.32
Outstanding Shares243,163,000

Return

Return on Equity7.39%ROE
Return on Assets5.58%
Return on Invested Capital9.52%

Valuation & Multiples

P/E Ratio37.28P/E Ratio
PEG-48.84PEG
Price to Sales9.56Price to Sales
Price to Book Ratio2.88Price to Book Ratio
Enterprise Value to Revenue9.48
Enterprise Value to EBIT29.16
Enterprise Value to Net Income38
Total Debt to Enterprise0.07
Debt to Equity0.22Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS Estimate
$1653.73
Consensus analyst estimate
Revenue Estimate
$1457.78 B
Consensus analyst estimate

Next Earnings Call

Expected Date
March 3, 2027
EPS Estimate
$2036.87
Consensus analyst estimate
Revenue Estimate
$1633.21 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Celltrion, Inc.

3,153 employees
CEO: Woo-Sung Kee

Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Rem...